Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes

Cited by (860)

Items 101–200 of 860

1. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141
   Naomi Kiyota, Yasuhisa Hasegawa, Shunji Takahashi, Tomoya Yokota, Chia-Jui Yen, Shigemichi Iwae, Yasushi Shimizu, Ruey‐Long Hong, Masahiro Goto, Jin Hyoung Kang et al. · 2017 · Oral Oncology
2. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
   Aya Nakaya, Takayasu Kurata, Hiroshige Yoshioka, Yuki Takeyasu, Maiko Niki, Kayoko Kibata, Naoko Murakami Satsutani, Makoto Ogata, Takayuki Miyara, Shosaku� Nomura · 2018 · International Journal of Clinical Oncology
3. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
   Julia Judd, Matthew R. Zibelman, Elizabeth A. Handorf, John P. O’Neill, Chethan Ramamurthy, Sasini Bentota, Jamie Doyle, Robert G. Uzzo, Jessica Ruth Bauman, Hossein Borghaei et al. · 2017 · The Oncologist
4. Pulmonary sarcoid-like granulomatosis induced by nivolumab
   Henri Montaudié, Johana Pradelli, Thierry Passeron, J.‐P. Lacour, Sylvie Leroy · 2016 · British Journal of Dermatology
5. Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
   Kim, Hye In, Kim, Mijin, Lee, Se-Hoon, Park, So Young, Kim, Young Nam, Kim, Hosu, Jeon, Min Ji, Kim, Tae Yong, Kim, Sun Wook, Kim, Won Bae et al. · 2018 · OncoImmunology
6. PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
   Mustafa Khasraw, David A. Reardon, Michael Weller, John Howard Sampson · 2020 · Clinical Cancer Research
7. Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
   Fausto Petrelli, Giulia Grizzi, Michele Ghidini, Antonio Ghidini, Margherita Ratti, Stefano Panni, Mary Cabiddu, Mara Ghilardi, Karen Borgonovo, Maria Chiara Parati et al. · 2019 · Journal of Immunotherapy
8. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials
   Costa, Ricardo, Carneiro, Benedito A., Agulnik, Mark, Rademaker, Alfred W., Pai, Sachin G., Villaflor, Victoria M., Cristofanilli, Massimo, Sosman, Jeffrey A., Giles, Francis J. · 2017 · Oncotarget
9. Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis
   Yong Fan, Wenhui Xie, Hong Huang, Yunxia Wang, Guangtao Li, Yan Geng, Yanjie Hao, Zhuoli Zhang · 2021 · Frontiers in Oncology
10. Harnessing big data to characterize immune-related adverse events
    Jing, Ying, Yang, Jingwen, Johnson, Douglas B., Moslehi, Javid J., Han, Leng · 2022 · Nature Reviews Clinical Oncology
11. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
    Omar Hasan Ali, Stefan Diem, Eva Markert, Wolfram Jochum, Katrin Kerl, Lars Einar French, Daniel E. Speiser, Martin Früh, Lukas Flatz · 2016 · OncoImmunology
12. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways
    Bai, Xue, Fisher, David E., Flaherty, Keith T. · 2019 · Nature Reviews Clinical Oncology
13. Brief Report: Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience
    Michael D. Richter, Olga Pinkston, Lisa A. Kottschade, Heidi Diann Finnes, Svetomir N. Markovic, Uma Thanarajasingam · 2018 · Arthritis & Rheumatology
14. Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
    Laura Carpin Kennedy, Shailender Bhatia, John A. Thompson, Petros D. Grivas · 2019 · Journal of the National Comprehensive Cancer Network
15. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies
    Yoshiyuki Nakamura, Ryota Tanaka, Hiroshi Maruyama, Yosuke Ishitsuka, Naoko Okiyama, Rei Watanabe, Manabu Fujimoto, Yasuhiro Fujisawa · 2018 · Japanese Journal of Clinical Oncology
16. Cutaneous manifestations associated with immune checkpoint inhibitors
    Tomoya Watanabe, Yukie Yamaguchi · 2023 · Frontiers in Immunology
17. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non–Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors
    Jun Fukihara, Koji Sakamoto, Junji Koyama, Takayasu Ito, Shingo Iwano, Masahiro Morise, Masahiro Ogawa, Yasuhiro Kondoh, Tomoki Kimura, Naozumi Hashimoto et al. · 2019 · Clinical Lung Cancer
18. Checkpoint Inhibitor–Induced Colitis
    Emanuelle Bellaguarda, Stephen B. Hanauer · 2020 · The American Journal of Gastroenterology
19. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
    Yuko Oya, Tatsuya Yoshida, Hiroaki Kuroda, Masashi Mikubo, Chiaki Kondo, Junichi Shimizu, Yoshitsugu Horio, Yukinori Sakao, Toyoaki Hida, Yasushi Yatabe · 2017 · Oncotarget
20. Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity
    Aleksey K. Molodtsov, M. Turk · 2018 · Frontiers in Immunology
21. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
    Petros Fessas, Lucia A. Possamai, James Clark, Ella Daniels, Cathrin L. C. Gudd, Benjamin Harvey Mullish, James Leslie Alexander, David James Pinato · 2019 · Immunology
22. Epigenetic modifiers as new immunomodulatory therapies in solid tumours
    Sandrine Aspeslagh, Daphné Morel, Jean‐Charles Soria, Sophie C. Postel-Vinay · 2018 · Annals of Oncology
23. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma
    Caroline Robert, Wen‐Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S. Weber, ADIL I. DAUD, Frank Stephen Hodi, Jedd D. Wolchok, Tara C. Mitchell, Peter Hersey et al. · 2020 · European Journal of Cancer
24. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT
    Nobashi, Tomomi, Baratto, Lucia, Reddy, Sunil A., Srinivas, Sandhya, Toriihara, Akira, Hatami, Negin, Yohannan, Thomas K., Mittra, Erik · 2019 · Clinical Nuclear Medicine
25. Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
    Aaron Elliott Lisberg, D. Andrew Tucker, Jonathan Wade Goldman, Brian Wolf, James Carroll, Ariana Hardy, Karolyn K. Morris, Paulina Linares, Carlos R. Adame, Marshall L. Spiegel et al. · 2018 · Cancer Immunology Research
26. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab
    Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka, Takeru Funakoshi, Taku Fujimura, Yuki Yamamoto, Hiroo Hata, Masahiko Gosho, Ryota Tanaka, Kei Yamaguchi et al. · 2017 · Journal of Dermatological Science
27. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells
    Themis Alissafi, Aikaterini Hatzioannou, A.I. Legaki, Athina Varveri, Panayotis Verginis · 2019 · Journal of Autoimmunity
28. Strategies for improving the management of immune-related adverse events
    Aung Naing, Joud Hajjar, James L. Gulley, Michael B. Atkins, Gennaro Ciliberto, Funda Meric‐Bernstam, Patrick Hwu · 2020 · Journal for ImmunoTherapy of Cancer
29. Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study
    Okada, Naoto, Kawazoe, Hitoshi, Takechi, Kenshi, Matsudate, Yoshihiro, Utsunomiya, Ryo, Zamami, Yoshito, Goda, Mitsuhiro, Imanishi, Masaki, Chuma, Masayuki, Hidaka, Noriaki et al. · 2019 · Clinical Therapeutics
30. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study
    Alessio Cortellini, Federico Bozzetti, Pierpaolo Palumbo, Davide Brocco, Pietro Di Marino, Nicola Tinari, Michele De Tursi, Veronica Agostinelli, Leonardo Valerio Patruno, Cristina Valdesi et al. · 2020 · Scientific Reports
31. Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis
    Yee-Ming Melody Cheung, Wei Wang, Bradley Alexander McGregor, Ole‐Petter R. Hamnvik · 2022 · Cancer Immunology Immunotherapy
32. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
    Beung‐Chul Ahn, Kyoung‐Ho Pyo, Chun-Feng Xin, Dongmin Jung, Hyo Sup Shim, Chang Young Lee, Sung Yong Park, Hong In Yoon, Min Hee Hong, Byoung Chul Cho et al. · 2019 · Journal of Cancer Research and Clinical Oncology
33. Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism
    Jianqiong Yin, Yuanjun Wu, Xue Yang, Lu Gan, Jianxin Xue · 2022 · Frontiers in Immunology
34. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab
    Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, Chie Homma, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hirohito Kobayashi, Masayoshi Okumi et al. · 2019 · Urologic Oncology Seminars and Original Investigations
35. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab
    Mioko Matsuo, Ryuji Yasumatsu, Muneyuki Masuda, Satoshi Toh, Takahiro Wakasaki, Kazuki Hashimoto, Masahiko Taura, Ryutaro Uchi, Takashi Nakagawa · 2019 · Oral Oncology
36. Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer
    Khan, Zia, Di Nucci, Flavia, Kwan, Antonia, Hammer, Christian, Mariathasan, Sanjeev, Rouilly, Vincent, Carroll, Jonathan, Fontes, Magnus, Ley Acosta, Sergio, Guardino, Ellie et al. · 2020 · Proceedings of the National Academy of Sciences
37. Permissive Cardiotoxicity
    Charles Porter, Tariq U. Azam, Divyanshu Mohananey, Rohit Kumar, Jian Chu, Daniel John Lenihan, Susan Faye Dent, Sarju Ganatra, Gary S. Beasley, Tochukwu M. Okwuosa · 2022 · JACC CardioOncology
38. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma
    Hamzah Abu‐Sbeih, Faisal S. Ali, Wei Qiao, Yang Lü, Sapna Pradyuman Patel, Adi K. Diab, Yinghong Wang · 2019 · Cancer Immunology Immunotherapy
39. A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management
    Adriana T. Lopez, Larisa J. Geskin · 2018 · The Oncologist
40. CD47: the next checkpoint target for cancer immunotherapy
    Ridong Feng, Zhao Hai, Jianguo Xu, Chongyang Shen · 2020 · Critical Reviews in Oncology/Hematology
41. Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade
    Zia Khan, Christian Hammer, Jonathan Carroll, Flavia Di Nucci, Sergio Ley Acosta, Vidya Maiya, Tushar Bhangale, Julie Hunkapiller, Ira Mellman, Matthew L. Albert et al. · 2021 · Nature Communications
42. Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy
    Azael Freites‐Martínez, Bernice Y. Kwong, Kerri E. Rieger, Daniel G. Coit, Alexander Dimitrios Colevas, Mario E. Lacouture · 2017 · JAMA Dermatology
43. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update
    Kylie A. Fletcher, Douglas Buckner Johnson · 2024 · Journal for ImmunoTherapy of Cancer
44. Case of acute anterior uveitis and Vogt–Koyanagi–Harada syndrome‐like eruptions induced by nivolumab in a melanoma patient
    Takashi Arai, Kazutoshi Harada, Yoshihiko Usui, Ryokichi Irisawa, Ryoji Tsuboi · 2016 · The Journal of Dermatology
45. Sarcoid-like reactions in patients receiving modern melanoma treatment
    Florentia Dimitriou, Anna Lisa Frauchiger, Mirjana Urosevic‐Maiwald, Mirjam Nägeli, Simone M. Goldinger, Marjam Jeanette Barysch, Daniel Franzen, Jivko Kamarachev, Ralph Peter Braun, Reinhard Dummer et al. · 2018 · Melanoma Research
46. PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine
    Ramin S. Herati, David A. Knorr, Laura A. Vella, Luisa Victoria Silva, Lakshmi Chilukuri, Sokratis A. Apostolidis, Alexander Chan Chi Huang, Alexander Muselman, Sasikanth Manne, Oliva Kuthuru et al. · 2022 · Nature Immunology
47. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities
    Cousin, Sophie, Italiano, Antoine · 2016 · Clinical Cancer Research
48. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma
    Suo, Aleksi, Chan, Yin, Beaulieu, Carissa, Kong, Shiying, Cheung, Winson Y., Monzon, Jose G., Smylie, Michael, Walker, John, Morris, Don, Cheng, Tina · 2020 · The Oncologist
49. Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies
    Shelley Ji Eun Hwang, Giuliana Carlos, Shaun Chou, Deepal Wakade, Matteo Salvatore Carlino, Pablo Fernández‐Peñas · 2016 · Melanoma Research
50. Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors
    Li Zhong, Qing Wu, Fuchun Chen, Junjin Liu, Xianhe Xie · 2021 · Cancer Immunology Immunotherapy
51. Immune‐related adverse events are associated with improved response, progression‐free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors
    Corey Christian Foster, Marcus Couey, Sara E. Kochanny, Arun Khattri, Rajesh K. Acharya, Yi‐Hung Carol Tan, Ryan J. Brisson, Rom S. Leidner, Tanguy Y. Seiwert · 2021 · Cancer
52. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy
    Horisberger, Alice, La Rosa, Stefano, Zurcher, Jean-Philippe, Zimmermann, Stefan, Spertini, Francois, Coukos, George, Obeid, Michel · 2018 · Journal for ImmunoTherapy of Cancer
53. Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature
    Valentina Lo Preiato, Stefania Salvagni, C. Ricci, Andrea Ardizzoni, Uberto Pagotto, Carla Pelusi · 2021 · Reviews in Endocrine and Metabolic Disorders
54. Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events
    Ryosuke Matsukane, Hiroyuki Watanabe, Haruna Minami, Kojiro Hata, Kimitaka Suetsugu, Toshikazu Tsuji, Satohiro Masuda, Isamu Okamoto, Takashi Nakagawa, Takamichi Ito et al. · 2021 · Scientific Reports
55. Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials
    Yu Fujiwara, Nobuyuki Horita, Elio Adib, Susu Zhou, Amin H. Nassar, Zain Ul Abideen Asad, Alessio Cortellini, Abdul Rafeh Naqash · 2023 · The Lancet Oncology
56. Thyroid dysfunctions secondary to cancer immunotherapy
    Paulina Chalan, Giulia Di Dalmazi, Fabiana Pani, Alessandra De Remigis, Andrea Corsello, Patrizio Caturegli · 2017 · Journal of Endocrinological Investigation
57. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
    Christopher Alan Muir, Alexander Maxwell Menzies, Roderick John Clifton-Bligh, Venessa Tsang · 2020 · Thyroid
58. Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
    Laura Kalfeist, Loïck Galland, Fanny Ledys, François Ghiringhelli, Emeric Limagne, Sylvain Ladoire · 2022 · Cells
59. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience
    Chantel Cacciotti, Jungwhan John Choi, Sanda Alexandrescu, Mary Ann Zimmerman, Tabitha M. Cooney, Christine A. Chordas, Jessica R. Clymer, Susan N Chi, Kee Kiat Yeo · 2020 · Journal of Neuro-Oncology
60. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
    Ryan Joseph Sullivan, Michael B. Atkins, John M. Kirkwood, Sanjiv S. Agarwala, Joseph I. Clark, Marc S. Ernstoff, Leslie Anne Fecher, Thomas Frank Gajewski, Brian Gastman, David H. Lawson et al. · 2018 · Journal for ImmunoTherapy of Cancer
61. Immune checkpoint inhibitor-related thyroid dysfunction
    Shintaro Iwama, Tomoko Kobayashi, Yoshinori Yasuda, Hiroshi Arima · 2022 · Best Practice & Research Clinical Endocrinology & Metabolism
62. “How Much Time Do I Have?”: Communicating Prognosis in the Era of Exceptional Responders
    Thomas William LeBlanc, Jennifer S. Temel, Paul R. Helft · 2018 · American Society of Clinical Oncology Educational Book
63. The Role of Extracellular Vesicles in the Pathogenesis and Treatment of Autoimmune Disorders
    Mengrou Lu, Emma F. DiBernardo, Emily Parks, Hannah Fox, Siyang Zheng, Elizabeth C. Wayne · 2021 · Frontiers in Immunology
64. Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events
    Linda Chan, Shelley Ji Eun Hwang, Karen Byth, Merribel Kyaw, Matteo Salvatore Carlino, Shaun Chou, Pablo Fernández‐Peñas · 2019 · Journal of the American Academy of Dermatology
65. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation
    Huaxia Yang, Zhuoran Yao, Xiaoxiang Zhou, Wen Zhang, Xuan Zhang, Fengchun Zhang · 2020 · Clinical Immunology
66. Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis
    Igor J. Puzanov, Poornima Subramanian, Yan Yatsynovich, David M. Jacobs, Maya R. Chilbert, Umesh C. Sharma, Fumito Ito, Steven G Feuerstein, Filip Stefanovic, Benjamin Switzer et al. · 2021 · Journal for ImmunoTherapy of Cancer
67. Checkpoint inhibitor hepatotoxicity: pathogenesis and management
    Morven E. Cunningham, Rohit Gupta, Marcus Otho Butler · 2023 · Hepatology
68. Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians
    Sophie Outh-Gauer, Marie Alt, Christophe Le Tourneau, Jérémy Augustin, Chloé Broudin, Cassandre Gasne, Thomas Denize, H. Mirghani, Elizabeth Fabre, M. Ménard et al. · 2018 · Cancer Treatment Reviews
69. Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study
    Naoya Yamazaki, Yoshio Kiyohara, Hisashi Uhara, Jiro Uehara, Manabu Fujimoto, Tatsuya Takenouchi, Masaki Otsuka, Hiroshi Uchi, Hironobu Ihn, Hironobu Minami · 2017 · Cancer Science
70. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
    Fan Yang, Chloe Shay, Marin Ibrahim Abousaud, Chris Tang, Yamin Li, Zhaohui Steve Qin, Nabil F. Saba, Yong Teng · 2023 · Journal of Experimental & Clinical Cancer Research
71. Mogamulizumab for relapsed adult T‐cell leukemia–lymphoma: Updated follow‐up analysis of phase I and II studies
    Takashi Ishida, Atae Utsunomiya, Tatsuro Jo, Kazuhito Yamamoto, Koji Kato, Shinichiro Yoshida, Shigeki Takemoto, Hitoshi Suzushima, Yukio Kobayashi, Yoshitaka Imaizumi et al. · 2017 · Cancer Science
72. Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
    Sebastian Chrétien, Ioannis Zerdes, Jonas C. S. Bergh, Alexios Matikas, Theodoros Foukakis · 2019 · Cancers
73. Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
    Alessandro Inno, Giulio Metro, Paolo Bironzo, Antonio Maria Grimaldi, Elisabetta Grego, Vincenzo Di Nunno, Virginia Picasso, Francesco Massari, Stefania Gori · 2017 · Tumori Journal
74. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges
    Fang Yang, Jacqueline Wang, Yucai Wang, Baorui Liu, Julian R. Molina · 2021 · Cancers
75. Immune-related adverse events are linked with improved progression-free survival in patients receiving anti-PD-1/PD-L1 therapy
    Hammad Shafqat, Theodore Stewart Gourdin, Amy Marie Sion · 2018 · Seminars in Oncology
76. Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer—What Can We Learn from the Hematological Experience?
    Øystein Bruserud, Helene Hersvik Aarstad, Tor Henrik Anderson Tvedt · 2020 · Cancers
77. Biomarkers to predict prognosis and response to checkpoint inhibitors
    Takeshi Yuasa, Hitoshi Masuda, Shinya Yamamoto, Noboru Numao, Junji Yonese · 2017 · International Journal of Clinical Oncology
78. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade
    Genevieve J. Kaunitz, Manisha J. Loss, Hira A. Rizvi, Sowmya Ravi, Jonathan D. Cuda, Karen B. Bleich, Jessica Esandrio, Inbal B. Sander, Dung Thi Le, Luis Alberto Diaz et al. · 2017 · The American Journal of Surgical Pathology
79. Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review
    Marlies De Bock, Eva Hulstaert, Vibeke Krüse, Liève Brochez · 2018 · Case Reports in Dermatology
80. Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody
    Yusuke Tomita, Daisuke Sueta, Yosuke Kakiuchi, Sho Saeki, Koichi Saruwatari, Shinya Sakata, Takayuki Jodai, Yohei Migiyama, Kimitaka Akaike, Susumu Hirosako et al. · 2017 · Annals of Oncology
81. Nivolumab and Ipilimumab in Advanced Melanoma
    Emilio J Alegre-del-Rey, Blanca de la Nogal Fernández, Pilar Briceño-Casado · 2017 · New England Journal of Medicine
82. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
    Kevin Tyan, Joanna Bagińska, Martha Brainard, Anita Giobbie‐Hurder, Mariano Severgnini, Michael P. Manos, Rizwan Haq, Elizabeth Iannotti Buchbinder, Patrick Alexander Ott, Frank Stephen Hodi et al. · 2021 · Cancer Immunology Immunotherapy
83. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
    David James Pinato, Thomas Urban Marron, Pallavi Shruti Mishra-Kalyani, Yutao U. T. Gong, Guo Wei, David Szafron, Elad Sharon, Anwaar Saeed, Tomi Wei Jun, Sirish Dharmapuri et al. · 2021 · European Journal of Cancer
84. Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?
    Wolf H. Fridman, Sophie Sibéril, Guilhem Pupier, Sarah Soussan, Catherine Sautès‐Fridman · 2022 · Seminars in Immunology
85. Clinical characterization of colitis arising from anti-PD-1 based therapy
    Daniel Y. Wang, Meghan J. Mooradian, Dae Won Kim, Neil J. Shah, Sarah Elizabeth Fenton, Robert Martin Conry, Rutika Jitesh Mehta, Ann Willman Silk, Alice Yao Zhou, Margaret Compton et al. · 2018 · OncoImmunology
86. Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
    Paderi, Agnese, Giorgione, Roberta, Giommoni, Elisa, Mela, Marinella, Rossi, Virginia, Doni, Laura, Minervini, Andrea, Carini, Marco, Pillozzi, Serena, Antonuzzo, Lorenzo · 2021 · Cancers
87. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
    Dylan J. Martini, Lana Hamieh, Rana R. McKay, Lauren C. Harshman, Raphael Brandão Moreira, Craig K. Norton, John A. Steinharter, Katherine Maragaret Krajewski, Xin Yuan Gao, Fabio A. Schutz et al. · 2018 · Cancer Immunology Research
88. Keeping Expectations in Check With Immune Checkpoint Inhibitors
    Jennifer S. Temel, Justin F. Gainor, Ryan Joseph Sullivan, Joseph A. Greer · 2018 · Journal of Clinical Oncology
89. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients
    Alessio Cortellini, Sebastiano Buti, Veronica Agostinelli, Melissa Bersanelli · 2019 · Seminars in Oncology
90. Drug-induced sarcoidosis-like reactions
    Jelle Miedema, Hilario Nunès · 2021 · Current Opinion in Pulmonary Medicine
91. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma
    Jonathan Edward Brammer, Zachary Braunstein, Aashish Katapadi, Kyle M. Porter, Michael A. Biersmith, Avirup Guha, Sumithira Vasu, Vedat O. Yildiz, Sakima Ahmad Smith, Benjamin Harding Buck et al. · 2021 · Journal for ImmunoTherapy of Cancer
92. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors
    Chiara Ciccarese, Salvatore Alfieri, Matteo Santoni, Daniele Santini, Matteo Brunelli, Cristiana Bergamini, Lisa Francesca Licitra, Rodolfo Montironi, Giampaolo Tortora, Francesco Massari · 2015 · Expert Opinion on Drug Metabolism & Toxicology
93. Synergistic Local Combination of Radiation and Anti-Programmed Death Ligand 1 Immunotherapy Using Radiation-Responsive Splintery Metallic Nanocarriers
    Bongseo Choi, Hyunjun Choi, Bo Yu, Dong‐Hyun Kim · 2020 · ACS Nano
94. Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
    Michele Guida, Sabino Strippoli, Milena Maria Maule, Pietro Quaglino, Alice Ramondetta, Vanna Chiarion‐Sileni, Giancarlo Antonini Cappellini, Paola Queirolo, Laura Ridolfi, M. Del Vecchio et al. · 2021 · ESMO Open
95. Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer
    Leah Louisa Thompson, Nira A. Krasnow, Michael S. Chang, Jaewon Yoon, Edward B. Li, Nicole J. Polyakov, Gabriel E. Molina, Jordan Taylor Said, Kevin B. Huang, Juhi R. Kuchroo et al. · 2021 · JAMA Dermatology
96. Advanced Renal Cell Carcinoma: Role of the Radiologist in the Era of Precision Medicine
    Atul Bhanudas Shinagare, Katherine Maragaret Krajewski, Marta Braschi‐Amirfarzan, Nikhil H. Ramaiya · 2017 · Radiology
97. Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
    Chaoyue Su, Hui Wang, Yunru Liu, Qiaoru Guo, Lingling Zhang, Jiajun Li, Wenmin Zhou, Yanyan Yan, Xinke Zhou, Jianye Zhang · 2020 · Frontiers in Oncology
98. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report
    Kazuhiko Ikeuchi, Yusuke Okuma, Taku Tabata · 2016 · Lung Cancer
99. Biomarkers for Immune Checkpoint Inhibitors in Melanoma
    Shigehisa Kitano, Takayuki Nakayama, Makiko Yamashita · 2018 · Frontiers in Oncology
100. Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy
     Jingjing Su, Yiting Fu, Zitong Cui, Zain Ul Abıdın, Jingsong Yuan, Xinmiao Zhang, Runmin Li, Chunzhen Zhao · 2024 · Frontiers in Pharmacology